Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
Rydex Health Care H RYHAX
- NAV / 1-Day Return 36.07 / −0.11 %
- Total Assets 23.7 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.650%
- Distribution Fee Level High
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 268%
USD | NAV as of May 17, 2024 | 1-Day Return as of May 17, 2024, 10:16 PM GMT+0
Morningstar’s Analysis RYHAX
Will RYHAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings —
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 3.90 | 965,448 | Healthcare |
UnitedHealth Group Inc | 3.31 | 817,739 | Healthcare |
Johnson & Johnson | 3.00 | 741,911 | Healthcare |
Merck & Co Inc | 2.88 | 712,662 | Healthcare |
AbbVie Inc | 2.77 | 685,971 | Healthcare |
Thermo Fisher Scientific Inc | 2.24 | 555,056 | Healthcare |
Abbott Laboratories | 2.07 | 512,379 | Healthcare |
Danaher Corp | 1.98 | 488,702 | Healthcare |
Pfizer Inc | 1.96 | 484,487 | Healthcare |
Amgen Inc | 1.95 | 482,775 | Healthcare |